NAD+ findings under magnification
The blood numbers are impressive. The muscle experiment deserves the slower examination. Between those findings sits a medical reputation that deserves a closer examination.
What is NAD+?
NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme, a small helper molecule that enzymes need to do their work. Cells use it to move electrons while releasing energy from food; they also spend it on processes involving DNA repair and inflammation. The review of NAD+ metabolism during ageing lays out both jobs, which explains why this molecule attracts so much attention.
The plus sign identifies the electron-accepting form. After accepting electrons it becomes NADH, and the cycle continues. NAD+ has no amino-acid chain: it is a dinucleotide rather than a peptide. Those names matter when a page about peptides happens to mention it.
There is an appealing simplicity to the idea of replacing something cells need. But the biology already contains a complication: different enzymes draw on the same supply, and increasing that supply leaves a separate question about what the body actually does with it.
Blood NAD+ after NR
One of the most striking figures comes from an eight-week NR trial in healthy overweight adults. Nicotinamide riboside, shortened to NR, raised whole-blood NAD+ by 22% at 100 mg/day, 51% at 300 mg/day and 142% at 1000 mg/day. Those were the amounts administered in the experiment. Adverse events did not differ significantly from placebo, and no flushing was reported.
On its immediate question, the trial earns my confidence. An oral precursor reached the NAD+ pathway and changed a measurable result. The temptation is to let the largest percentage answer every other question as well: energy, ageing, disease prevention. The trial cannot carry all that weight.
Most oral research concerns precursors, ingredients the body converts into NAD+. Swallowed NAD+ itself is poorly absorbed intact. The NR bioavailability experiments help explain why the ingredient inside a NAD supplement deserves as much attention as the name on the front. The NMN vs NR comparison opens that part of the file.
Muscle and walking
The experiment I take more seriously as a clue to function involved prediabetic, postmenopausal women. After NMN at 250 mg/day for 10 weeks, muscle insulin sensitivity improved. In other words, muscle responded better to the hormone that helps it handle sugar. HbA1c, the longer-term blood-sugar measure, and body composition stayed unchanged.
That combination is interesting precisely because the improvement was specific. A separate multicenter NMN trial reported improved walking distance as well as higher blood NAD+. These results give the subject something more substantial than a laboratory number, while leaving plenty for another experiment to resolve.
My enthusiasm goes to those narrower findings. The human results deserve room to be examined individually, alongside the much stranger work on mouse eyes and drug-resistant melanoma cells.
The infusion question
Putting NAD+ straight into a vein sounds like a way around the oral-delivery problem. Yet the six-hour infusion pilot found near-complete removal of infused NAD+ from plasma during roughly the first two hours. Plasma is the fluid around blood cells. Delivery to that fluid still leaves the question of how the molecule is processed and what reaches a particular tissue.
The delivery story turned out messier than I expected. Instead, the infusion file contains rapid clearance, limited controlled evidence and practical safety concerns. IV NAD+ observations need their own examination; an oral NR result cannot stand in for them.
The 2025 review of human ageing trials found limited efficacy and sparse tissue-specific measurements. For now, the most productive next question seems quite concrete to me: which people gain a useful change in function, and does it last?